Wound contraction is attenuated by fasudil inhibition of Rho-associated kinase.

Division of Plastic and Reconstructive Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Plastic and Reconstructive Surgery (Impact Factor: 3.33). 11/2011; 128(5):438e-450e. DOI: 10.1097/PRS.0b013e31822b7352
Source: PubMed

ABSTRACT Dermal scarring and scar contracture result in restriction of movement. There are no effective drugs to prevent scarring. RhoA and Rho-associated kinase have emerged as regulators of fibrosis and contracture. Fasudil, a Rho-associated kinase inhibitor, has been demonstrated to have antifibrotic effects in models of liver, renal, and cardiac fibrosis. The role of fasudil in preventing dermal scarring and contractures has not been studied. The authors used a rat model of dermal wound healing to assess the effects of fasudil with regard to the prevention of scarring.
Human scar tissue and surrounding normal skin were immunostained for RhoA and Rho-associated kinase. Full-thickness wounds were created on Wistar-Han rats, and fasudil (30 mg/kg/day) or saline was continuously delivered subcutaneously. Wound contraction was measured by gravitational planimetry. After 21 days, tissue was harvested for Masson's trichrome, hematoxylin and eosin, Ki-67, and CD31 staining. Fibroblast-populated collagen lattices were used to assess the mechanistic effects of fasudil on contractility. Myofibroblast formation was assessed in the presence of fasudil.
Human scar tissue in the remodeling phase of repair showed increased expression of RhoA and Rho-associated kinase in scar tissue compared with surrounding normal tissue. Fasudil inhibited wound contraction as compared with controls. Hematoxylin and eosin and Masson's trichrome were similar between groups. Fasudil did not alter angiogenesis or proliferation. Fasudil inhibited fibroblast contractility and myofibroblast formation in vitro.
There is growing evidence that the RhoA/Rho-associated kinase pathway plays an important role in wound healing and scar contracture. The authors present data showing that inhibition of Rho-associated kinase hinders fibroblast contractility and may be beneficial in preventing scar contracture.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The process of cutaneous wound healing and contraction is a complex orchestra of temporally and spatially controlled signaling moieties and pathways. Rho-kinase (ROCK) has been implicated as a key downstream effector of transforming growth factor β1 (TGF-β1) signal transduction, which ultimately coordinates α-smooth muscle actin (α-SMA)-mediated wound contraction. Previous in vitro studies of ROCK inhibition have demonstrated decreased fibroblast contraction and epithelial advancement after wounding. In vivo systemic ROCK inhibition revealed modest late wound healing attenuation in contrast to α-SMA knock-out rodents. The goal of this investigation was to explore the effect of local delivery of a ROCK inhibitor on an in vivo murine model of wound healing. Full-thickness cutaneous wounds were created in 24 white mice and were treated daily with local topical delivery of 100 μL of 10 M ROCK inhibitor (Y27632) or saline control. Percent wound surface area over time and compensatory epithelial advancement was quantified. After 12 days, tissue was harvested for assessment of inflammatory cellular density, immunohistochemistry for α-SMA, and TGF-β protein expression. Wounds subjected to local ROCK inhibition were significantly larger than controls at early time points, and this effect of delayed wound contraction in ROCK-inhibited wounds persisted for 7 days after wounding (P < 0.05). The effect of ROCK inhibition on delay of wound contraction was normalized at day 12. There was no significant difference between control and ROCK-inhibited groups in the area of the nascent epithelium beyond the wound margin, wound inflammatory cellular density, and TGF-β1 expression. However, ROCK inhibition led to as statistically significant decrease in α-SMA stress fiber formation compared to controls [32.5% (3.5%) vs 17.4% (2.6%); P < 0.05]. Local delivery of a ROCK inhibitor delayed the time course of murine wound contraction in a manner similar to that previously reported in α-SMA knock-out rodents, thus demonstrating an effective method for in vivo ROCK inhibition. Accordingly, α-SMA stress fiber formation was inhibited in treated wound beds without altering local inflammation, TGF-β1 expression, or epithelial wound edge advancement.
    Annals of plastic surgery 03/2014; · 1.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Prostaglandin E2 (PGE2) signaling mechanism within fibroblasts is of growing interest as it has been shown to prevent numerous fibrotic features of fibroblast activation with limited evidence of downstream pathways. In order to understand the mechanisms of fibroblasts producing tremendous amounts of PGE2 with autocrine effects, we apply a strategy of combining a wide-screening of PGE2-induced kinases with quantitative phosphoproteomics. Our large-scale proteomic approach identified a PKA signal transmitted through phosphorylation of its substrates harboring the R(R/X)X(S*/T*) motif. We documented 115 substrates, of which 72 had 89 sites with a 2.5-fold phosphorylation difference in PGE2 treated cells than in untreated cells, where approximately half of such sites were defined as being novel. They were compiled by networking software to focus on highlighted activities and to associate them with a functional readout of fibroblasts. The substrates were associated with a variety of cellular functions including cytoskeletal structures (migration/motility), regulators of G-protein coupled receptor function, protein kinases, and transcriptional/translational regulators. For the first time, we extended the PGE2 pathway into an elaborate network of interconnecting phosphoproteins, providing vital information to a once restricted signalosome. These data provide new insights into eicosanoid-initiated cell signaling with regards to the regulation of fibroblast activation and the identification of new targets for evidenced-based pharmacotherapy against fibrosis.
    Journal of Proteome Research 09/2014; · 5.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Scarring continues to present a significant clinical problem. Wound contraction leads to scarring and is mediated by myofibroblasts and contractile forces across the wound bed. Contracture formation can have a significant impact on the quality of life of the patient, particularly where function and appearance are affected. Novel tissue-engineered matrices, cell-based therapies, and medicinal therapeutics have shown significant reduction in wound contraction in in-vivo models, particularly at early time points. These have been accompanied in many cases by reduced numbers of myofibroblasts, and in some by increased angiogenesis and improved neodermal architecture. There are no animal models that replicate all aspects of wound healing as seen in patients. Therefore, information obtained from in vivo studies should be assessed critically. Additional studies, in particular those that seek to elucidate the mechanisms by which novel therapies reduce contraction, are needed to gain sufficient confidence to move into clinical testing. The use of knockout mouse models in particular has generated significant advances in knowledge of the mechanisms behind myofibroblast conversion and other factors involved in generating tension across the wound. Medicinal therapeutics and tissue-engineering approaches that seek to disrupt/alter these pathways hold much promise for future development and translation to clinical practice.
    Advances in wound care. 05/2013; 2(4):167-175.

Full-text (2 Sources)

Available from
May 27, 2014